IDegLira receives CHMP positive opinion

Aug 13, 2014 EDT

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion, recommending marketing authorisation for Xultophy for the treatment of type 2 diabetes mellitus in adults.
Xultophy is the intended brand name for IDegLira, the first once-daily single injection combination of Tresiba (insulin degludec) and Victoza (liraglutide), developed for the treatment of type 2... 

Like Us on Facebook

Trending NOW

Real Time Analytics